The company struck a deal with the U.S. Justice Department and the Federal Trade Commission to resolve charges related to the marketing and sales of Suboxone Film.
Federal prosecutors claimed that Reckitt “illegally obtained billions of dollars in revenue” by tricking healthcare providers into believing that Suboxone is safer and less susceptible to abuse than similar drugs although its active ingredient is an opioid.
The settlement is the largest financial penalty issued that’s tied to the opioid crisis, according to the report.
Suboxone film is used to treat addiction to other drugs like heroin. It’s made by Reckitt’s former pharma arm, Indivior, which became a stand-alone company in 2014.
More articles on pharmacy:
Judge blocks HHS rule requiring drug prices in TV ads
Nation’s 1st prescription drug affordability board goes into effect
11 healthcare pharma leaders offer advice on controlling drug spend
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
